Why Collegium Pharmaceutical, Inc.’s (COLL) Stock Is Up 10.14%
As of Thursday, August 13, Collegium Pharmaceutical, Inc.’s COLL share price has surged by 10.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Collegium Pharmaceutical, Inc. (COLL)
Collegium Pharmaceutical, Inc. COLL
$28.74
0.24
0.84%
August 19, 2026 4:00:00 PM
EST
Volume: 769,362
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Commentary & Analysis
Is Collegium Pharmaceutical, Inc. (COLL) Overvalued?
We dive into why Collegium Pharmaceutical, Inc. (COLL) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Collegium Pharmaceutical, Inc.’s (COLL) Stock Is Down 6.04%
As of Monday, August 10, Collegium Pharmaceutical, Inc.’s COLL share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Collegium Pharmaceutical, Inc.’s (COLL) Stock Is Down 10.86%
As of Thursday, August 06, Collegium Pharmaceutical, Inc.’s COLL share price has dipped by 10.86%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Collegium Pharmaceutical, Inc.’s (COLL) Stock Is Down 12.79%
As of Thursday, August 06, Collegium Pharmaceutical, Inc.’s COLL share price has dipped by 12.79%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | COLL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $896.9 | $618.0 | 44% |
|
| Shares Out (Mil) | 32.5 | 44.8 | 38% |
|
| Institutional Ownership | 99.1% | 85.3% | 85% |
|
| Float (Mil) | 32.2 | 47.4 | 38% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 963 | 390 | 70% |
|
| Price Change (52-week) |
(26.8%) | 68.6% | 25% |
|
| Growth | COLL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 20.3% | 6.7% | 82% |
|
| Net Income (5yr) | 18.6% | (1.6%) | 71% |
|
| EPS (5yr) | 17.9% | 14.9% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 91.6% | (14.9%) | 98% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $1.861 | $7.466 | $6.766 | |
| Month Ago EPS | $2.091 | $7.765 | $7.505 | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $2.077 | $7.720 | $7.612 | |
| Year/Year Chg | (501.1%) | 330.3% | 235.7% | |
| Financials | COLL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $808 | $291 | 47% |
|
| Net Income (TTM) (Mil) | $48 | ($11) | 55% |
|
| EPS (TTM) | $1.500 | ($0.700) | 66% |
|
| Operating Cash Flow (TTM) (Mil) | $330 | ($6) | 66% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $5 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $1,161 | $6 | 68% |
|
| Enterprise Value (Q1) (Mil) | na | $450 | na |
|
| Valuation | COLL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.87 | 2.78 | 63% |
|
| P/E | 19.6 | 17.4 | 50% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.1 | 1.1 | 48% |
|
| Ratios | COLL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 89.4% | 67.0% | 93% |
|
| Net Margin | 5.9% | (2.3%) | 51% |
|
| ROA | 2.6% | (22.4%) | 59% |
|
| ROE | 17.6% | (20.2%) | 76% |
|
| Liabilities to Assets | 85.4% | 32.2% | 79% |
|
| F-Score | 5 | 3 | 50% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Free-Cash-Flow Screen
Factors: Value
An exploration of the basics of cash flow analysis and the implementation of a price-to-free-cash-flow screen.
| Performance Since Inception: | 16.7% |
| +/- S&P 500: | +9.2 |
